Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review
October 26, 2026
October 26, 2026
LEVERKUSEN, Germany, Oct. 26 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:
* * *
Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review
*
Berlin, October 26, 2026 - Bayer announced today that China's National Medical Products Administration (NMPA) has granted marketing authorization for asundexian, under the bran . . .
* * *
Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review
*
Berlin, October 26, 2026 - Bayer announced today that China's National Medical Products Administration (NMPA) has granted marketing authorization for asundexian, under the bran . . .
